A recent Dermatology digest,
as sent to subscribers

Study Type: Randomised clinical equivalence trial

Key Question: Does an asynchronous, online team-based connected health (TCH) model produce equivalent improvements in atopic dermatitis severity compared to conventional in-person care over 12 months?

Key Findings:

• EASI difference between groups: −0.01 (95% CI −0.22 to 0.20); within equivalence margins
• POEM and vIGA differences were similarly within prespecified equivalence bounds across 300 participants (149 TCH, 151 in-person)
• Clinical equivalence was demonstrated across all three primary and secondary outcomes at 12 months

Clinical Relevance: With NHS dermatology facing sustained demand pressures and geographic access inequity, this trial supports asynchronous teledermatology as a clinically equivalent alternative to in-person AD management, strengthening the evidence base for scalable remote care pathways.

Limitations: The trial was conducted across California outpatient clinics, limiting direct generalisability to NHS settings with differing workforce structures, referral pathways, and patient demographics.

Study Type: Insufficient data — the abstract contains no extractable content.

Key Question: Cannot be determined from the information provided.

Key Findings:

• No abstract text was supplied for analysis.
• The title suggests a case report or case series describing verrucous plaques following Blaschko's lines on the lower limb, likely relating to a mosaic/epidermal naevus disorder or linear inflammatory dermatosis.
• No findings, data, or conclusions can be summarised.

Clinical Relevance: Blaschko-linear verrucous lesions are a recognised diagnostic challenge in dermatology, relevant to conditions such as epidermal naevi, ILVEN, and mosaic genodermatoses — a topic of clinical importance in secondary care.

Limitations: No abstract was provided; this summary is based solely on the article title and cannot substitute for review of the full text.

Study Type: Systematic review (qualitative synthesis; meta-analysis not performed due to heterogeneity)

Key Question: Which clinical, laboratory, or treatment-related factors predict progression from acute to chronic urticaria?

Key Findings:

• Progression rates varied widely (5.8–36.0%) across 16 studies (n=52,564), partly attributable to tertiary centre selection bias, variable follow-up, and inconsistent outcome definitions.
• No clinical feature (disease severity, angioedema, atopy, allergic sensitisation) or laboratory marker (total IgE, eosinophil count, neutrophil-to-lymphocyte ratio, autoantibodies) was reproducibly associated with chronicity.
• Systemic corticosteroid use during acute urticaria did not reduce progression risk, arguing against aggressive early treatment to prevent chronicity.

Clinical Relevance: UK dermatologists and allergists cannot currently risk-stratify acute urticaria patients using available markers; structured follow-up rather than escalated acute treatment is the appropriate management approach.

Limitations: All included studies carried moderate-to-high risk of bias, with significant methodological heterogeneity precluding quantitative pooling.

Study Type: Retrospective reader study with convolutional neural network development

Key Question: Does an AI-assisted deep learning model improve dermatology residents' diagnostic accuracy for lentigo maligna (LM) versus other facial pigmented lesions on dermoscopy?

Key Findings:

• The Xception-based model achieved 84.2% accuracy, 90.8% sensitivity, and 81.9% specificity for classifying LM, pigmented actinic keratosis, and seborrhoeic keratosis/solar lentigo
• Resident diagnostic accuracy improved from 64.9% to 74.0% with AI assistance (p<0.0001), with LM detection showing the greatest gain (+16.5%)

Clinical Relevance: LM on chronically sun-damaged facial skin is a recognised diagnostic challenge in UK dermatology; AI-assisted dermoscopy could reduce missed diagnoses and support registrar training, relevant given workforce pressures on NHS dermatology services.

Limitations: Retrospective single-centre design with residents only as readers limits generalisability to consultant-level practice and real-world clinical workflows.

Study Type: Prospective, single-arm, multi-centre clinical trial

Key Question: Does oral ivarmacitinib (selective JAK1 inhibitor) improve clinical outcomes and modulate immune pathways in palmoplantar pustulosis over 12 weeks?

Key Findings:

• Mean PPPASI fell from 11.3 to 3.9 (p<0.001) at 12 weeks; 85% achieved PPPASI50, though only 13.3% reached PPPASI75
• Pruritus, pain, and QoL improvements were evident by week 2
• Baseline immune markers (lower CD4/CD8 ratio, Th2/Th1 ratio, IL10RA/IL2RB) predicted early response, suggesting potential for biomarker-guided patient selection

Clinical Relevance: PPP has few licensed systemic therapies in the UK; this adds prospective evidence for a selective JAK1 inhibitor as a candidate treatment, with rapid symptom onset potentially meaningful for patient burden.

Limitations: The uncontrolled single-arm design precludes conclusions about comparative efficacy or placebo effect.

Study Type: Retrospective cohort study with patient satisfaction survey

Key Question: Does long-term low-dose capecitabine reduce keratinocyte carcinoma (KC) surgical burden in patients with topical-refractory cutaneous field cancerisation?

Key Findings:

• Statistically significant reduction in KC surgeries at year 2 (73% reduction; 3.46 to 0.93 procedures/year; p=0.02); reductions at years 1 and 3 did not reach significance
• Discontinuation due to toxicity occurred in 10% (2/20 patients)
• 75% of survey respondents reported at least moderate skin improvement; 83% preferred capecitabine over prior treatments

Clinical Relevance: For UK dermatologists managing immunocompromised or high-KC-burden patients refractory to topical field treatments, this supports capecitabine as a potential systemic option, though it remains off-label in this context.

Limitations: Very small sample (n=20), single-centre retrospective design, and limited follow-up numbers at year 3 (n=5) substantially restrict generalisability and statistical power.

Study Type: Retrospective analysis of Global Burden of Disease (GBD) dataset

Key Question: What is the global epidemiological burden of skin diseases, and how does this vary by region, age, and sex?

Key Findings:

• Skin and subcutaneous diseases (excluding STIs and skin cancers) affected 25.7% of the global population in 2021, ranking sixth in global disease prevalence with a YLD rate of 495.1 per 100,000 person-years
• Keratinocyte carcinomas (SCC, BCC) and pressure ulcers showed increasing prevalence 2000–2021; atopic dermatitis, scabies, and viral skin infections declined slightly
• Chronic inflammatory and neoplastic conditions predominated in high-income regions, mirroring the NHS dermatology caseload

Clinical Relevance: This data reinforces the scale of dermatological need in high-income settings and supports advocacy for NHS dermatology resource allocation and workforce planning.

Limitations: GBD data substantially underestimates true burden due to limited inclusion of dermatological conditions, underreporting, and poor-quality data from low- and middle-income countries.

Study Type: Case-control study (single-centre, exploratory proteomic analysis)

Key Question: Does systemic inflammation in hidradenitis suppurativa vary with disease stage, severity, and quality of life?

Key Findings:

• 37 of 92 immune proteins were significantly elevated in HS patients vs matched controls; top upregulated mediators included TGF-α, IL-6, OSM, IL-8/CXCL8, and IL-17A
• Systemic inflammation was present even in mild (Hurley stage I) disease, with TGF-α, OSM, IL-8, IL-7, and HGF already elevated at this stage
• IL-6 and HGF correlated positively with both IHS4 severity scores and DLQI; IL-17A and CCL19 associated with longer disease duration

Clinical Relevance: These findings support treating HS as a systemic inflammatory disease from early stages, strengthening the rationale for biologics targeting IL-17A and IL-6 pathways within NHS practice.

Limitations: Small cohort (n=44 per group) with potential confounding from BMI and smoking limits generalisability.